Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MK2 Inhibitor ATI-450 in Healthy Subjects: A Placebo-Controlled, Randomized Phase 1 Study

David N. Gordon, Edward T. Hellriegel, Heidi Rath Hope, David Burt, Joseph B. Monahan
ISSN / E-ISSN
— / —
DOI
10.2147/cpaa.s305308 ↗
Volume · Issue · Pages
Volume 13 · — · 123-134
Publisher
Dove Medical Press Ltd.
Article URL
https://doi.org/10.2147/cpaa.s305308 ↗
Article details
Unverified
Publication date (each date has its type and source)
01 Jun 2021
OpenAlex publication date · source: OpenAlex
Dates on record for this article
TypeDateSource
OpenAlex publication date01 Jun 2021 OpenAlex

Keywords (as given): MK2 inhibitors; p38 MAPK; MAPKAPK2; inflammatory signaling; cytokine inhibition; TNF-α; IL-1β; interleukin-6; interleukin-8; pharmacokinetics; pharmacodynamics; safety and tolerability; dose proportionality; healthy volunteers; anti-inflammatory agents

HEC Status at Publication Not the journal's current status

HEC Status at PublicationNot conclusive
Best available information, not a definitive status: HEC status cannot be determined for this date: no HEC list is recorded as in effect on it.
Journal
Clinical Pharmacology: Advances and Applications
Publication date used
01 Jun 2021 (OpenAlex publication date)
Applicable HEC period
None recorded for this date
Category
—
Recognition status
Unknown (NO_PERIOD_FOR_DATE)
Source
—
Verification status
Not available
This is an automatically generated summary based on the information available on the publication date. Terms & conditions apply.